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Background/aim: Hepatic resection is a potentially curative treatment for patients with hepatocellular carcinoma (HCC). Controversy
persists regarding preoperative and intraoperative characteristics related to patient survival in various medical institutes. This study
aimed to evaluate the impact of preoperative and intraoperative factors on the long-term survival of patients with HCC who underwent
hepatectomy.
Materials and methods: Data on 455 patients with HCC who underwent hepatectomy over a 20-year period were retrospectively reviewed.
Univariate and multivariate Cox regression analyses were performed for preoperative- and intraoperative-related prognostic factors.
Results: The 1-, 3-, 5-, and 10-year overall survival rates of patients with HCC who underwent resection were 76.3%, 57.9%, 46.7%,
and 27.4%, respectively. Multivariate analyses identified four independent predictors of long-term prognosis—sex (male versus female,
hazard ratio [HR] = 2.732, p = 0.026); differentiation (poor versus well, HR = 2.037, p = 0.030); total bilirubin value (μmol/L, HR =
1.056, p = 0.033); and intraoperative blood transfusion (no transfusion versus transfusion, HR = 0.417, p = 0.002). Hepatitis virus B
infection (negative versus positive, HR = 0.669, p = 0.232) and resection style (anatomical versus nonanatomical, HR = 0.698, p = 0.181)
were not associated with survival.
Conclusion: Based on this 20-year study, poor survival of patients with HCC who underwent hepatectomy was correlated with
preoperative and intraoperative factors including male sex, poor differentiation, increased total bilirubin levels, and intraoperative
blood transfusion.
Key words: Hepatocellular carcinoma, prognosis, survival study, hepatectomy, perioperative

1. Introduction
In the past, the incidence of hepatocellular carcinoma
(HCC) varied widely globally, with high rates in sub-Saharan
Africa, eastern and southeastern Asia, and Melanesia and
low rates in Northern and Western Europe and America
[1]. However, it is now rapidly becoming more prevalent
in Western countries owing to the spread of hepatitis C
infection and increased rate of liver cancer associated with
alcohol use and nonalcoholic steatohepatitis [2]. HCC is,
therefore, increasingly becoming a major contributor to
the worldwide cancer burden. HCC is a histological type
of primary liver cancer and originates from hepatocytes
[3]. In the 17th Nationwide Follow-up Survey of Primary
Liver Cancer in Japan [4], 18,213 individuals were newly

registered as patients with primary liver cancer at 645
medical institutions, and 94.2% of these patients had
HCC. The incidence rates of this disease have increased
in many countries in recent decades [5]. As the principal
histological type of liver cancer, HCC accounts for the vast
majority of liver cancer diagnoses and deaths.
Currently, hepatic resection is a potentially curative
treatment for patients with malignant liver lesions,
especially HCC. The surgical outcome of HCC is affected
by many factors [6]. However, further research is needed
on ways to optimize the perioperative factors of HCC to
improve the effect of surgical intervention for HCC [7].
Therefore, we retrospectively investigated the data on
455 patients with HCC who underwent hepatectomy and
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were followed up to identify the impact of preoperative
and intraoperative factors on long-term prognosis.
2. Materials and methods
2.1. Patients
In total, 455 patients with HCC who underwent
hepatectomy and subsequent follow-ups were enrolled
in this investigation according to their medical records.
Diagnoses were based on pathological examination.
Death within 30 days of hepatic resection or at any time
after 30 days was considered surgical death. Patients
who experience surgical death and those who died
during the hospitalization period for hepatectomy were
excluded.
On admission, all selected patients had records
containing information on thorough disease histories
and physical examination findings. Preoperative data
on patient demographic information, diagnosis, and
laboratory blood analyses (bilirubin and alkaline
phosphatase levels) were also collected. Intraoperative
data on operation duration, estimated blood loss (EBL),
resected regions, and other related items were collected
from operation notes and anesthetist records. Data on
blood transfusion during surgery were also recorded.
Data regarding the resected specimen, including the
number of tumors and size of the largest tumor, were
obtained from pathology records.
Postoperative variables included complications and
survival rates. Data on long-term outcomes (survival
rates) were obtained through clinical follow-up and by
contacting the patient and family members, if necessary.
This study was approved by the Ethics Committee of
Chinese PLA General Hospital and used anonymized data.
2.2. Statistical analysis
All data are expressed as the percentage of patients or
as mean with standard deviation (SD). Survival rate was
calculated. Plots were constructed using the Kaplan–
Meier method and compared using the log-rank test
between groups. Cox regression was used to estimate the
risk for death (hazard ratio [HR]) for prognostic factors.
Differences with p < 0.05 were considered statistically
significant.
3. Results
3.1. Demographic information
From January 1999 to December 2019, 455 patients
with primary liver cancer underwent hepatectomy and
were followed up. These patients included 398 men and
57 women, with mean (± SD) age of 50.15 ± 10.48 years
(range 8–77 years). The tumor size ranged from 1 to 33
cm in diameter. Tumors measuring 5–10 cm were found in
158 (34.7%) patients, while those measuring >10 cm were
found in 75 (16.5%) patients.
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3.2. Complications
The postoperative complication rate was 9.9%; the
complications are summarized in Table 1. The most
common complications were related to liver cirrhosis,
including pleural effusion, ascites, and sterile perihepatic
fluid collection. All complications were managed
successfully by general treatment, such as concentrated
human albumin transfusion, adjustment of water and
electrolyte balance, and/or use of diuretics.
3.3. Patient survival
The 1-, 3-, 5- and 10-year overall survival rates of patients
with HCC who underwent resection were 76.3%, 57.9%,
46.7%, and 27.4%, respectively. Several preoperative
and operative variables associated with survival rates in
univariate analysis are summarized in Table 2, including
sex (p = 0.001), alpha-fetoprotein (p < 0.001), total bilirubin
(p < 0.001), alkaline phosphatase (p = 0.013), Child–Pugh
score (p = 0.003), tumor size (p < 0.001), number of lesions
(p = 0.006), differentiation (p < 0.001), adjacent organ
resection (p < 0.001), ≥ 3 segments resected (p = 0.048),
resection style (p = 0.002), operative duration (p = 0.002),
intraoperative blood loss (p < 0.001), and intraoperative
blood transfusion (p = 0.001). Multivariate analyses (as
shown in Tables 3 and 4) identified four independent
predictors of long-term prognosis—sex (male versus
female, HR = 2.732, p = 0.026), differentiation (poor
versus well, HR = 2.037, p = 0.030), intraoperative blood
transfusion (no transfusion versus transfusion: HR = 0.417,
p = 0.002), and total bilirubin level (μmol/L: HR = 1.056,
p = 0.033). Hepatitis B virus (HBV) infection (negative
versus positive: HR = 0.669, p = 0.232) and resection style
(anatomical versus nonanatomical: HR = 0.698, p = 0.181)
were not correlated with survival.
4. Discussion
4.1. Complications of hepatectomy among patients with
HCC
Hepatectomy is a complex and difficult surgical
technique. Despite technical advances and extensive
experience with liver resection in specialized centers,
hepatectomy is associated with relatively high rates of
postoperative morbidity. The four potentially devastating
complications of liver resection include postoperative
hemorrhage, venous thromboembolism, bile leakage,
and posthepatectomy liver failure [8]. The risk factors
and management of these complications were herein
explored, stressing the importance of identifying
preoperative factors that could decrease the risk for these
potentially fatal complications. Some perioperative factors
responsible for the increase in complications are as follows
[9]: American Society of Anesthesiologists classification;
patient age, platelet count, intraoperative EBL, and tumor
number. In this study, the postoperative complication rate
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for HCC was 9.9%. The most common complications were
related to liver cirrhosis, including pleural effusion, ascites,
and sterile perihepatic fluid collection. All complications
were managed successfully by general treatment, such as
concentrated human albumin transfusion, adjustment of
water and electrolyte balance, or use of diuretics.
4.2. Overall survival rates of patients with HCC who
underwent hepatectomy
The survival rates for HCC after liver resection vary
among medical institutes. Chen [10] reported that the
mean expected survival times and survival rates at 5 years
were 77.8 months and 47.1%, respectively. In a study
by Lee [11], the 1-, 3-, and 5-year overall survival rates
were 91.9%, 78.9%, and 69.5%, respectively, and the 1-,
3-, and 5-year recurrence-free survival rates were 71.7%,
51.7%, and 43.7%, respectively. A study involving 1330
consecutive patients reported that the overall survival
rates at 1, 3, and 5 years were 91.2%, 63.3%, and 36.9%,
respectively, and the disease-free survival rates at 1, 3,
and 5 years were 67.7%, 33.7%, and 13.8%, respectively
[12].

4.3. Controversial clinical characteristics associated with
patient survival
The incidence of HCC coincident with liver cirrhosis is
increasing in some high-epidemic areas of HBV infection.
In this study, hepatitis B surface antigen was tested in 423
patients, among whom 337 (79.7%) showed positivity. The
1-, 3-, 5- and 10-year survival rates in the HBV group were
75.1%, 56.0%, 45.4%, and 28.4%, respectively, and those in
the non-HBV group were 82.6%, 64.8%, 50.7%, and 30.6%,
respectively. There were no significant differences between
their survival rates (p = 0.073). However, a study by Wu
[13] indicated that the 1- and 3-year recurrence-free
survival rates of HBV-negative patients were significantly
better than those of HBV-positive patients (66% and 25%
versus 89% and 70%). However, there were no significant
differences in the 1-, 3-, and 5-year overall survival rates
between the groups.
The liver resection style was an important factor
associated with prognosis. It is unclear whether hepatectomy
for HCC should be performed as an anatomical resection
(AR) or a non-AR (NAR). No randomized controlled

Table 1. Postoperative complications.
Complication

Number

Ratio (%)

Incisional wound infection

1

0.22

Pelvic cavity fluid collection

1

0.22

Retroperitoneum fluid collection

1

0.22

Stress ulcer

1

0.22

Alimentary tract hemorrhage

1

0.22

Abdominal cavity/raw surface bleeding

1

0.22

Hepatic inadequacy

1

0.22

Bile leakage

2

0.44

Wound liquefaction

2

0.44

Renal inadequacy

3

0.66

Incision disruption

4

0.88

Periliver fluid collection (sterile)

8

1.76

Ascites

12

2.64

Deep venous thrombosis (lower extremity)

2

0.44

Pneumothorax

2

0.44

Atelectasis

2

0.44

Pneumonia

6

1.32

Pleural effusion

19

4.18

2

0.44

Abdomen

Pulmonary and cardiovascular

Others
Fever of unknown origin
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Table 2. Univariate analysis of factors associated with survival rate

Variable

Number

Survival rate (%)
1-year

3-year

5-year

10-year

p-value*

Sex
Male

398

74.1

55.2

44.0

24.8

Female

57

91.2

77.0

65.3

46.5

0.001

≤40

67

70.1

56.4

50.0

32.3

41–50

177

78.5

55.3

45.1

30.8

51–60

127

74.8

55.0

42.1

22.3

84

88.1

69.0

55.4

31.2

≤20

98

84.7

74.2

61.0

26.8

>20

217

74.7

49.7

39.0

20.1

≤21

258

80.2

63.2

54.1

35.4

>21

144

70.1

46.1

32.9

0

≤130

292

77.1

58.6

49.4

28.9

>130

56

67.9

46.2

34.6

19.2

Negative

86

82.6

64.8

50.7

30.6

Positive

337

75.1

56.0

45.4

28.4

5

293

79.5

60.5

51.6

33.8

0.003

6

74

68.9

50.7

41.5

7

25

60

51.7

35.2

8

12

34.3

9

4

50

≤5

222

85.6

70.0

57.0

30.1

0.000

5–10

158

70.9

47.5

39.7

24.7

>10

75

60.0

43.8

33.0

24.4

Single

400

77.5

59.9

49.2

28.8

Multiple

54

66.7

43.8

24.7

18.5

Well

69

91.3

69.2

64.1

46.7

Moderate

183

78.7

58.5

45.3

14.0

Poor

86

58.1

40.2

37.3

22.1

No

409

76.8

57.1

46.8

26.2

Yes

46

71.7

60.4

46.3

46.3

Age (years)

>60

0.309

Alpha-fetoprotein (ng/ml)

#

0.000

Total bilirubin (μmol/L)#
0.000

Alkaline phosphatase (U/L)#
0.013

Hepatitis B surface antigen#
0.073

Child–Pugh score#

Largest tumor size (cm)

Number of lesions#
0.006

Differentiation#
0.000

Previous abdominal surgery
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Table 2. (Continued).
Laparoscopic resection
No
Yes
Adjacent organ resection
No
Yes
≥ 3 segments resected
No
Yes
Resection style
Nonanatomical
Anatomical
Operative duration (min)
≤ 180
> 180
Intraoperative blood loss (mL)
≤ 400
> 400
Intraoperative blood transfusion
No
Yes
Incisional margin
Residual tumor
No residual tumor
Complication
No
Yes
*

437
18

75.7
83.3

57.1
72.2

45.9
66.7

27.0

0.140

450
5

76.9
20.0

58.5

47.2

27.7

0.000

303
152

79.9
69.1

61.1
51.7

50.3
38.3

29.9
21.7

0.048

351
104

79.5
65.4

61.9
44.4

49.7
36.5

29.7
21.7

0.002

267
188

80.9
69.7

62.2
51.8

52.6
38.4

33.3
19.7

0.002

328
127

81.7
62.2

61.9
47.3

51.1
34.9

30.5
18.4

0.000

262
193

83.6
66.3

63.0
51.0

52.3
38.9

39.6
20.4

0.001

4
451

50.0
76.3

50.0
57.7

27.2
46.7

0

0.943

410
45

77.3
66.7

57.9
57.6

47.0
43.7

28.0
24.3

0.637

Log-rank (Mantel–Cox) test
Missing data

#

trials addressing this topic are currently available. Jiao
[14] searched for articles investigating AR versus NAR
for HCC published between January 1998 and December
2018 in the PubMed, Cochrane Library, EMBASE, and
Wanfang databases. Metaanalysis was performed on
patient characteristics, tumor characteristics, operative
characteristics, perioperative outcomes, and long-term
outcomes. Thirty-eight studies involving 9122 patients
were included, among whom 5062 were included in the AR
group and 4060 were included in the NAR group. The AR
group exhibited better 1-, 3-, and 5-year overall survival
and disease-free survival rates than the NAR group.
Our results were different from these findings. In our
study, the 1-, 3-, 5- and 10-year survival rates were 79.5%,
61.9%, 49.7%, and 29.7%, respectively, in the NAR group
and 65.4%, 44.4%, 36.5%, and 21.7%, respectively, in the
AR group. Univariate analysis indicated that survival rates
in the NAR group were significantly higher than those in

the AR group (p = 0.002). However, multivariate analysis
indicated that survival was not correlated with resection
style (p = 0.181). The advantages of NAR appear to be
twofold— conserving liver function and reducing the
dangers associated with more extensive liver resections.
This is particularly advantageous in patients who may be at
higher risk for AR, such as those with cirrhosis and those
with a small remnant liver. Some studies have indicated that
small-for-size livers are more conducive to tumor growth
and metastasis [15, 16]. Liver regeneration after major
surgery may activate occult micrometastases and facilitate
tumor growth, leading to liver tumor recurrence [17].
The incidence rate of not only liver cirrhosis but also
HBV infection is high in China. Liver cirrhosis is the
primary cause of liver cancer in China. Liver function
reserve in patients with cirrhosis is poor. The use of AR
will result in more liver tissue loss than the use of NAR,
and the probability of postoperative liver insufficiency
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will increase. Therefore, consistent with our study results,
AR has no advantage over NAR in Chinese patients with
liver cirrhosis. However, given that hepatectomy is mostly
performed in the absence of cirrhosis in Europe, the United
States, and other countries, AR has been recommended in
literature reports involving patients outside of China as
research subjects.
In a retrospective study, Wong [18] reported that
elevated alpha-fetoprotein levels, low albumin levels, and
tumors measuring >5 cm were associated with increased
1-year mortality after hepatic resection for early-stage
HCC. Kondo [19] reported that alkaline phosphatase level
(> 125 U/L), alpha-fetoprotein level (within 20–400 or >400
ng/mL), protein induced by vitamin K absence-II (within

40–400 or > 400 mAU/mL), tumor number, diameter,
pseudocapsule, tumor growth pattern, and intratumor
hemorrhage were independent prognostic factors for
HCC. In our study, multivariate analyses indicated that the
total bilirubin value (μmol/L, HR = 1.056, p = 0.033) was
an independent predictor of poor survival for HCC, and
Child–Pugh status was not correlated with survival.
Limited studies have reported correlations between
long-term survival and intraoperative factors, such as
blood loss and blood transfusion. Several studies have
suggested that preoperative blood loss or transfusions have
a negative impact on postoperative outcomes. However,
it is unclear whether this is due to a real cause–effect
relationship or merely the result of a more complicated

Table 3. Multivariate analysis of factors associated with survival (numeration data).
Variable
Sex

Hazard ratio (95% confidence
interval)

Female

1.000-

Male

2.732 (1.129–6.613)

P value*

0.026

HBsAg
Positive

1.000-

Negative

0.669 (0.347–1.292)

0.232

Differentiation
Well

1.000-

Moderate

1.237 (0.702–2.178)

0.462

Poor

2.037 (1.071–3.877)

0.030

Previous abdominal surgery
Yes

1.000-

No

1.716 (0.706–4.170)

0.233

≥3 segments resected
Yes

1.000-

No

1.603 (0.988–2.601)

0.056

Resection style
Anatomical

1.000-

Nonanatomical

0.698 (0.412–1.182)

0.181

Intraoperative blood loss (ml)
≤400

1.000-

>400

1.313 (0.717–2.405)

0.378

Intraoperative blood transfusion
Yes

1.000-

No

0.417 (0.239–0.726)

0.002

Complication(s)
Yes

1.000-

No

0.769 (0.368–1.603)

Cox regression
HBsAg, hepatitis B surface antigen
*
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Table 4. Multivariate analysis of factors associated with survival (measurement data).
Variable

Hazard ratio (95% CI)

p-value*

Age (years)

1.008 (0.986–1.030)

0.481

Alpha-fetoprotein (ng/mL)

1.000 (1.000–1.000)

0.481

Total bilirubin (μmol/L)

1.056 (1.004–1.110)

0.033

Alkaline phosphatase (U/L)

1.003 (0.999–1.007)

0.143

Child–Pugh score

0.955 (0.679–1.343)

0.791

Largest tumor size (cm)

1.003 (0.997–1.009)

0.366

Operative time (min)

1.000 (0.998–1.003)

0.766

Cox regression

*

surgery. The effect of blood transfusions on tumor
recurrence and long-term mortality is much less clear,
and evidence varies depending on the type of malignancy
[20]. In our study, univariate analysis indicated that the
survival rates among cases involving intraoperative blood
loss <400 mL were significantly higher than those among
cases involving intraoperative blood loss was >400 mL
(p < 0.001). The survival rates in the no intraoperative
blood transfusion group were significantly higher than
those in the intraoperative blood transfusion group (p
= 0.001). However, multivariate analysis indicated that
only intraoperative blood transfusion was a prognostic
indicator associated with a higher risk for death (no
transfusion versus transfusion, HR = 0.417, p = 0.002).
4.4. Conclusion
The prognostic factors for HCC after hepatectomy are
controversial. In our 20-year study, the poor survival of
patients with HCC who underwent hepatectomy was
correlated with preoperative and intraoperative factors
including male sex, poor differentiation, increased total
bilirubin levels, and intraoperative blood transfusion, but
not with HBV infection or resection style.
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